{"0": {"cll": 0.6430772542953491, "refractory cll": 0.6103479266166687, "cll sll": 0.5509762167930603, "cancer therapy": 0.4871905744075775, "clinical trials": 0.4811354875564575, "clinical trial": 0.4705432057380676, "treatments": 0.4689864218235016, "treatment options": 0.46396857500076294, "treatment": 0.4469330310821533, "therapeutics announces": 0.44517630338668823, "combination therapies": 0.4418884515762329, "targeted therapies": 0.44011470675468445, "targeted therapy": 0.4377482831478119, "treatment landscape": 0.43269023299217224, "tg therapeutics": 0.43147921562194824, "monotherapy": 0.41466450691223145, "cell therapy": 0.40554147958755493, "patients with chronic": 0.4042210578918457, "combination therapy": 0.4009195864200592, "therapeutics": 0.39940881729125977, "chemotherapy": 0.39793604612350464, "btk inhibitors": 0.39387214183807373, "treatment naive": 0.39148008823394775, "newly diagnosed": 0.3884769678115845, "treatment paradigm": 0.388197124004364, "therapeutic": 0.3880292773246765, "was diagnosed": 0.3851052522659302, "chemotherapy free": 0.3842889666557312, "btk inhibitor": 0.38187175989151, "disease progression": 0.37975457310676575, "mcl": 0.37588411569595337, "clinical": 0.3745063245296478, "previously treated": 0.3740689158439636, "cel": 0.366182416677475, "therapies": 0.3644420802593231, "btk inhibition": 0.3535303473472595, "leukemia": 0.35212278366088867, "patients": 0.3515174984931946, "diagnosed": 0.3505014181137085, "wbc": 0.3496719002723694, "pi inhibitors": 0.3465922772884369, "cancer survivors": 0.3460395336151123, "oncology": 0.3423933982849121, "hematologist oncologist": 0.3420645594596863, "fda approval": 0.33689332008361816, "therapy": 0.3358183801174164, "prognostic": 0.335679292678833, "immunotherapy": 0.33543330430984497, "leukaemia": 0.32616016268730164, "inhibitors": 0.32611680030822754}, "1": {"lymphocytic leukemia": 0.8277190923690796, "lymphocytic leukaemia": 0.7805031538009644, "leukemia": 0.6735067963600159, "chronic lymphocytic": 0.6457443833351135, "leukaemia": 0.6380504369735718, "leukemia hematology": 0.6252689361572266, "lymphocytic": 0.5678176879882812, "lymphoma": 0.5431572198867798, "cell malignancies": 0.5200892090797424, "hematologic malignancies": 0.5004295110702515, "malignancies": 0.4957338273525238, "cancer therapy": 0.494853138923645, "small lymphocytic": 0.484775573015213, "blood cancers": 0.47258153557777405, "lymphocyte": 0.4689182937145233, "chemotherapy": 0.4658496081829071, "blood cancer": 0.4573386609554291, "lymphocyte count": 0.45616209506988525, "cell therapy": 0.4541183114051819, "follicular lymphoma": 0.44745567440986633, "tumor lysis": 0.44498932361602783, "lymphocytes": 0.4252259433269501, "cancer survivors": 0.42354509234428406, "hematologist oncologist": 0.42257943749427795, "oncology": 0.4165310263633728, "chemotherapy free": 0.40872156620025635, "cancers": 0.40831437706947327, "cancer": 0.404845267534256, "immunotherapy": 0.3932729661464691, "lymph": 0.38956499099731445, "lymph nodes": 0.3827105462551117, "newly diagnosed": 0.3814886808395386, "disease progression": 0.36544305086135864, "cancer network": 0.36331915855407715, "cancer center": 0.36154332756996155, "hematology advisor": 0.3596476912498474, "targeted therapy": 0.352272629737854, "diagnosed": 0.3521839678287506, "wbc": 0.3500925600528717, "clinical trials": 0.33793044090270996, "was diagnosed": 0.3374409079551697, "patients with chronic": 0.33703815937042236, "my wbc": 0.3357394337654114, "targeted therapies": 0.33440566062927246, "treatments": 0.33348166942596436, "marrow": 0.33322495222091675, "enlarged lymph": 0.33293068408966064, "oncologist": 0.33014345169067383, "tg therapeutics": 0.32384172081947327, "therapeutics announces": 0.31628721952438354}, "2": {"ibrutinib plus": 0.617425799369812, "ibrutinib": 0.6010403633117676, "plus obinutuzumab": 0.4707673490047455, "btk inhibitors": 0.43004727363586426, "obinutuzumab": 0.4235380291938782, "obinutuzumab combo": 0.4152495563030243, "btk inhibitor": 0.41348886489868164, "venetoclax obinutuzumab": 0.4097786843776703, "plus rituximab": 0.3715968728065491, "refractory cll": 0.36959004402160645, "inhibitors": 0.36955440044403076, "cll": 0.36781108379364014, "treatment options": 0.355970561504364, "btk inhibition": 0.3555182218551636, "clinical trials": 0.35498446226119995, "combination therapies": 0.3548986613750458, "treatment": 0.34976714849472046, "treatments": 0.34157276153564453, "inhibitor": 0.34109920263290405, "targeted therapies": 0.3386431336402893, "acalabrutinib demonstrates": 0.3355711102485657, "clinical trial": 0.3341107964515686, "rituximab combo": 0.3245507776737213, "targeted therapy": 0.320341020822525, "rituximab": 0.3158717751502991, "therapeutics announces": 0.31181472539901733, "immunotherapy": 0.307794451713562, "zanubrutinib": 0.30337032675743103, "cll sll": 0.2971324920654297, "treatment naive": 0.28861314058303833, "tg therapeutics": 0.28604936599731445, "monotherapy": 0.2829296588897705, "cancer therapy": 0.2827763557434082, "wbc": 0.2787528336048126, "treatment landscape": 0.27647438645362854, "side effects": 0.2714846730232239, "previously treated": 0.27036261558532715, "therapeutics": 0.2696968913078308, "acalabrutinib": 0.26842570304870605, "cirmtuzumab": 0.26748499274253845, "disease progression": 0.2674490213394165, "pi inhibitors": 0.26719555258750916, "patients with chronic": 0.26427677273750305, "my wbc": 0.2641749978065491, "combination therapy": 0.26389139890670776, "chemotherapy": 0.261284738779068, "cell therapy": 0.2545338273048401, "chemotherapy free": 0.25093647837638855, "treatment paradigm": 0.24876128137111664, "plus venetoclax": 0.24582797288894653}, "3": {"car cells": 0.6380544900894165, "cell therapy": 0.6193737983703613, "car cell": 0.6021173596382141, "cancer therapy": 0.5234586000442505, "clinical trials": 0.44457945227622986, "cell transplant": 0.44374334812164307, "treatments": 0.4352513551712036, "tg therapeutics": 0.434309720993042, "cell malignancies": 0.4283530116081238, "targeted therapies": 0.4279181957244873, "clinical trial": 0.42141222953796387, "targeted therapy": 0.41459211707115173, "combination therapies": 0.407710999250412, "chemotherapy": 0.40636876225471497, "chemotherapy free": 0.39265328645706177, "therapeutics announces": 0.38796111941337585, "treatment": 0.3865281343460083, "treatment options": 0.38595661520957947, "therapies": 0.37744781374931335, "cell": 0.37342721223831177, "monotherapy": 0.3669224679470062, "cells": 0.3635227680206299, "treatment naive": 0.36312180757522583, "cd car": 0.35745179653167725, "immunotherapy": 0.3568768799304962, "cancer survivors": 0.3510296940803528, "therapeutics": 0.3479360342025757, "car nk": 0.34521055221557617, "treatment landscape": 0.34224390983581543, "combination therapy": 0.33659040927886963, "therapeutic": 0.33075833320617676, "treatment paradigm": 0.3305845260620117, "btk inhibitor": 0.33026954531669617, "cancer": 0.32792675495147705, "cancer center": 0.32737380266189575, "fda approval": 0.32653218507766724, "btk inhibitors": 0.32610347867012024, "oncology": 0.3241237699985504, "blood cancers": 0.3210553228855133, "blood cancer": 0.3207681179046631, "lymphocytic leukemia": 0.31535834074020386, "leukemia": 0.31241875886917114, "therapy": 0.3112336993217468, "fda approves": 0.3110387325286865, "chemo": 0.3055039942264557, "lymphocytes": 0.3051725924015045, "cancer network": 0.3051612377166748, "patients with chronic": 0.30427080392837524, "cancers": 0.3037108778953552, "fda": 0.30333685874938965}, "4": {"covid vaccine": 0.6885204911231995, "immunotherapy": 0.5442157983779907, "fully vaccinated": 0.5336582660675049, "covid": 0.5136502385139465, "vaccines": 0.5129953622817993, "vaccine": 0.50443434715271, "vaccinated": 0.5036736726760864, "vaccination": 0.4947439432144165, "lymphocytic leukaemia": 0.4604989290237427, "immune response": 0.44439980387687683, "chronic lymphocytic": 0.43791663646698, "lymphocyte count": 0.4368528723716736, "blood cancer": 0.4360302984714508, "newly diagnosed": 0.4309220314025879, "lymphocytic leukemia": 0.42919260263442993, "blood cancers": 0.41638582944869995, "immune system": 0.4134693741798401, "immune": 0.4122438132762909, "lymphocytic": 0.4121260941028595, "disease progression": 0.41186562180519104, "antibody": 0.39775267243385315, "hematologic malignancies": 0.39524251222610474, "lymphoma": 0.3937903046607971, "antibodies": 0.3896367847919464, "hematologist oncologist": 0.38955193758010864, "malignancies": 0.38795968890190125, "cancer therapy": 0.3821329176425934, "lymphocyte": 0.3780980110168457, "was diagnosed": 0.3775979280471802, "small lymphocytic": 0.3769989013671875, "leukaemia": 0.37594419717788696, "cancer survivors": 0.37097376585006714, "cell malignancies": 0.3681914806365967, "chemotherapy free": 0.36146092414855957, "diagnosed": 0.3585222661495209, "chemotherapy": 0.3579156994819641, "infection": 0.3503090739250183, "wbc": 0.3493952751159668, "leukemia": 0.34917765855789185, "patients": 0.34394371509552, "cell therapy": 0.33863556385040283, "treatment options": 0.3383020758628845, "clinical trials": 0.33816730976104736, "my wbc": 0.3346511721611023, "monotherapy": 0.33175861835479736, "younger patients": 0.3261834383010864, "targeted therapy": 0.32449647784233093, "oncologist": 0.32162800431251526, "leukemia hematology": 0.31985652446746826, "previously treated": 0.31789955496788025}, "5": {"venetoclax": 0.704944372177124, "venetoclax based": 0.6987351179122925, "plus venetoclax": 0.6796989440917969, "venetoclax obinutuzumab": 0.655861496925354, "venclexta": 0.5470594763755798, "cll": 0.4982798099517822, "refractory cll": 0.48269951343536377, "rituximab combo": 0.4235527217388153, "cll sll": 0.4231891930103302, "rituxan": 0.4169231653213501, "plus rituximab": 0.41063544154167175, "rituximab": 0.3696230947971344, "tg therapeutics": 0.3641791343688965, "btk inhibitors": 0.36092162132263184, "btk inhibitor": 0.35272473096847534, "lymphocytic leukemia": 0.34192776679992676, "combination therapies": 0.33707737922668457, "plus obinutuzumab": 0.33605048060417175, "inhibitors": 0.3200768232345581, "wbc": 0.3197998106479645, "chronic lymphocytic": 0.3196328282356262, "treatment options": 0.31687211990356445, "obinutuzumab combo": 0.3155999779701233, "lymphocytic leukaemia": 0.31374698877334595, "lymphoma": 0.3123665153980255, "cancer therapy": 0.3068196177482605, "therapeutics announces": 0.30672797560691833, "btk inhibition": 0.30554062128067017, "chemotherapy": 0.3051893711090088, "treatments": 0.3012644648551941, "targeted therapies": 0.3002997934818268, "inhibitor": 0.2988784909248352, "cell therapy": 0.29795679450035095, "lymphocytic": 0.2977789044380188, "treatment": 0.29442286491394043, "clinical trials": 0.29207491874694824, "chemotherapy free": 0.29105204343795776, "mcl": 0.29013121128082275, "lymph nodes": 0.2890610098838806, "targeted therapy": 0.2870706021785736, "clinical trial": 0.2860496938228607, "previously treated": 0.28171050548553467, "pi inhibitors": 0.28120917081832886, "immunotherapy": 0.2775375545024872, "lymphocyte count": 0.2768140733242035, "small lymphocytic": 0.263271301984787, "obinutuzumab": 0.2624456286430359, "treatment naive": 0.26205408573150635, "treatment landscape": 0.2620094418525696, "combination therapy": 0.26034414768218994}, "6": {"btk inhibitors": 0.8507791757583618, "btk inhibitor": 0.8328276872634888, "btk inhibition": 0.7713106274604797, "inhibitors": 0.48330825567245483, "inhibitor": 0.46020635962486267, "pi inhibitors": 0.4573170244693756, "cll": 0.45292019844055176, "cancer therapy": 0.43716615438461304, "tg therapeutics": 0.4320147633552551, "targeted therapies": 0.41424041986465454, "btk": 0.41148412227630615, "targeted therapy": 0.40131568908691406, "lymphocytic leukemia": 0.39085814356803894, "cell therapy": 0.3821268081665039, "chemotherapy": 0.3738320469856262, "lymphocytic leukaemia": 0.36703139543533325, "cll sll": 0.36117023229599, "combination therapies": 0.3600054383277893, "refractory cll": 0.3596959114074707, "treatments": 0.35261204838752747, "therapeutics announces": 0.3471605181694031, "obinutuzumab combo": 0.344874769449234, "lymphoma": 0.33850008249282837, "venetoclax obinutuzumab": 0.3355562090873718, "plus obinutuzumab": 0.33460062742233276, "treatment": 0.3333198130130768, "chronic lymphocytic": 0.32908153533935547, "therapeutics": 0.3287627100944519, "tumor lysis": 0.3265593349933624, "wbc": 0.32196009159088135, "leukemia": 0.3190074563026428, "chemotherapy free": 0.3179967403411865, "treatment options": 0.31162768602371216, "lymphocytic": 0.31149929761886597, "monotherapy": 0.3108783960342407, "therapeutic": 0.3106343150138855, "leukaemia": 0.3103616237640381, "clinical trials": 0.30445948243141174, "cell malignancies": 0.3019610643386841, "treatment naive": 0.3015104830265045, "hematologic malignancies": 0.300633043050766, "obinutuzumab": 0.30007079243659973, "leukemia hematology": 0.2998839318752289, "immunotherapy": 0.29821398854255676, "therapies": 0.2944991886615753, "blood cancers": 0.2932516932487488, "combination therapy": 0.29108425974845886, "my wbc": 0.2870887517929077, "clinical trial": 0.28268247842788696, "inhibition": 0.2792816758155823}, "7": {"acalabrutinib demonstrates": 0.7391288876533508, "acalabrutinib": 0.7151687741279602, "acalabrutinib shows": 0.6505751609802246, "zanubrutinib": 0.46009019017219543, "refractory cll": 0.42151641845703125, "plus obinutuzumab": 0.4209113121032715, "cll": 0.4062955379486084, "btk inhibitors": 0.4037522077560425, "obinutuzumab": 0.39966198801994324, "obinutuzumab combo": 0.3931425213813782, "btk inhibitor": 0.39005520939826965, "venetoclax obinutuzumab": 0.3467249572277069, "inhibitors": 0.3429984748363495, "fda approval": 0.3366369605064392, "cll sll": 0.3353688716888428, "pi inhibitors": 0.33379602432250977, "plus rituximab": 0.32840079069137573, "inhibitor": 0.3280472457408905, "cancer therapy": 0.3280313014984131, "btk inhibition": 0.32456687092781067, "fda approves": 0.32442328333854675, "treatment": 0.3198015093803406, "targeted therapies": 0.3165941536426544, "combination therapies": 0.3127131164073944, "fda": 0.3122229278087616, "therapeutics announces": 0.3098013997077942, "treatment options": 0.30784064531326294, "rituximab combo": 0.30525821447372437, "tg therapeutics": 0.3050335645675659, "ibrutinib plus": 0.3039869964122772, "treatments": 0.29824399948120117, "targeted therapy": 0.297019362449646, "cirmtuzumab": 0.29186201095581055, "rituximab": 0.2913983464241028, "ibrutinib": 0.2896891236305237, "clinical trial": 0.28410854935646057, "clinical trials": 0.27440255880355835, "treatment landscape": 0.27266746759414673, "treatment naive": 0.27171841263771057, "therapeutics": 0.2659100592136383, "refractory chronic": 0.2640712261199951, "chemotherapy": 0.26027441024780273, "chemotherapy free": 0.26010560989379883, "cell therapy": 0.2587481439113617, "abbvie": 0.2538447380065918, "monotherapy": 0.25367972254753113, "immunotherapy": 0.25235289335250854, "remission": 0.24619024991989136, "previously treated": 0.24305757880210876, "therapeutic": 0.24266541004180908}, "8": {"rituximab": 0.6367638111114502, "plus rituximab": 0.6351398229598999, "rituximab combo": 0.609861433506012, "rituxan": 0.5362688899040222, "venetoclax obinutuzumab": 0.4830959439277649, "plus obinutuzumab": 0.44240373373031616, "ibrutinib plus": 0.4369726777076721, "fda approval": 0.4118098020553589, "ibrutinib": 0.40149325132369995, "fda approves": 0.3885291814804077, "obinutuzumab": 0.38774603605270386, "clinical trials": 0.3844268321990967, "btk inhibitors": 0.38114282488822937, "inhibitors": 0.3739503026008606, "clinical trial": 0.36774590611457825, "obinutuzumab combo": 0.3668063282966614, "btk inhibitor": 0.3631252646446228, "fda": 0.3615875840187073, "plus venetoclax": 0.35949277877807617, "therapeutics announces": 0.3581124246120453, "targeted therapies": 0.35778456926345825, "venetoclax based": 0.35657480359077454, "inhibitor": 0.35061711072921753, "chemotherapy free": 0.3397769033908844, "cirmtuzumab": 0.3388117849826813, "cancer therapy": 0.3299528956413269, "cll": 0.3297842741012573, "targeted therapy": 0.32733654975891113, "venetoclax": 0.31689462065696716, "combination therapies": 0.31225210428237915, "refractory cll": 0.311514288187027, "acalabrutinib demonstrates": 0.3105742931365967, "fda grants": 0.3077656030654907, "chemotherapy": 0.3075532913208008, "treatment": 0.30495309829711914, "pi inhibitors": 0.3012096881866455, "treatment options": 0.3007233142852783, "treatments": 0.29673150181770325, "treatment naive": 0.29354327917099, "zanubrutinib": 0.29191073775291443, "treatment landscape": 0.2894899845123291, "tg therapeutics": 0.2865256071090698, "venclexta": 0.2863454222679138, "captivate trial": 0.28334853053092957, "immunotherapy": 0.28211987018585205, "btk inhibition": 0.2730753421783447, "monotherapy": 0.270509272813797, "cll sll": 0.2681916654109955, "acalabrutinib": 0.26712942123413086, "therapeutics": 0.2649359107017517}, "9": {"venetoclax obinutuzumab": 0.7670290470123291, "plus obinutuzumab": 0.6068025827407837, "obinutuzumab combo": 0.5966578722000122, "obinutuzumab": 0.5831676721572876, "venetoclax": 0.548690676689148, "venetoclax based": 0.5474782586097717, "plus venetoclax": 0.5410714745521545, "btk inhibitors": 0.41474413871765137, "venclexta": 0.4081362187862396, "btk inhibitor": 0.4028034508228302, "targeted therapies": 0.38590118288993835, "combination therapies": 0.3850645422935486, "cll": 0.38347068428993225, "refractory cll": 0.3693162798881531, "wbc": 0.3656931519508362, "tg therapeutics": 0.3576282858848572, "plus rituximab": 0.3564317524433136, "inhibitors": 0.35526418685913086, "therapeutics announces": 0.3542359471321106, "targeted therapy": 0.35371148586273193, "rituximab combo": 0.35181233286857605, "treatment options": 0.3514791429042816, "cancer therapy": 0.3513781428337097, "chemotherapy": 0.337545782327652, "clinical trials": 0.33683842420578003, "chemotherapy free": 0.3323046565055847, "lymphoma": 0.3306208848953247, "clinical trial": 0.3284932076931, "immunotherapy": 0.32808786630630493, "inhibitor": 0.32511988282203674, "rituxan": 0.3243170380592346, "treatment naive": 0.3215199410915375, "lymphocytic leukaemia": 0.3201797604560852, "treatments": 0.31934142112731934, "treatment": 0.31929636001586914, "lymphocytic leukemia": 0.3165197968482971, "btk inhibition": 0.31568479537963867, "my wbc": 0.31240344047546387, "disease progression": 0.30566930770874023, "rituximab": 0.3055744171142578, "cll sll": 0.3055601716041565, "chronic lymphocytic": 0.3010418713092804, "acalabrutinib demonstrates": 0.3006576895713806, "cell therapy": 0.2931533753871918, "zanubrutinib": 0.29237034916877747, "previously treated": 0.2914658188819885, "newly diagnosed": 0.29102057218551636, "patients with chronic": 0.28658175468444824, "treatment landscape": 0.28399011492729187, "monotherapy": 0.27835994958877563}, "10": {"venetoclax obinutuzumab": 0.6642903089523315, "venetoclax based": 0.6123902201652527, "plus venetoclax": 0.6088606119155884, "venetoclax": 0.6029367446899414, "ibrutinib plus": 0.5118181705474854, "ibrutinib": 0.463461697101593, "plus obinutuzumab": 0.4486297369003296, "venclexta": 0.4197911024093628, "plus rituximab": 0.4058723449707031, "obinutuzumab combo": 0.38999468088150024, "btk inhibitors": 0.3846108317375183, "cll": 0.38164904713630676, "obinutuzumab": 0.3791811466217041, "btk inhibitor": 0.37444746494293213, "refractory cll": 0.3698433041572571, "rituximab combo": 0.36415719985961914, "inhibitors": 0.3522755205631256, "rituxan": 0.3384692072868347, "rituximab": 0.33692795038223267, "cll sll": 0.33056241273880005, "combination therapies": 0.32950359582901, "inhibitor": 0.32452836632728577, "treatment options": 0.31976884603500366, "btk inhibition": 0.3131861090660095, "tg therapeutics": 0.30482253432273865, "clinical trials": 0.3041236996650696, "wbc": 0.29871895909309387, "therapeutics announces": 0.29706519842147827, "treatment": 0.2937712073326111, "clinical trial": 0.2928280234336853, "treatments": 0.287565678358078, "immunotherapy": 0.28404924273490906, "targeted therapies": 0.2804165184497833, "previously treated": 0.2750168442726135, "acalabrutinib demonstrates": 0.27460071444511414, "treatment naive": 0.2623489499092102, "treatment landscape": 0.24869588017463684, "targeted therapy": 0.24759425222873688, "zanubrutinib": 0.24611082673072815, "pi inhibitors": 0.24587321281433105, "my wbc": 0.24530029296875, "cirmtuzumab": 0.24462375044822693, "side effects": 0.24065610766410828, "chemotherapy": 0.2396050989627838, "chemotherapy free": 0.23920947313308716, "efficacy": 0.23292721807956696, "fda approval": 0.23144108057022095, "fda approves": 0.2302262932062149, "disease progression": 0.22592666745185852, "lymphocytic leukaemia": 0.22484102845191956}, "11": {"lymphocytic leukemia": 0.6610862016677856, "lymphocytic leukaemia": 0.6307222843170166, "venetoclax obinutuzumab": 0.5834107398986816, "venetoclax": 0.5658562779426575, "venetoclax based": 0.5645357370376587, "plus venetoclax": 0.5434195399284363, "chronic lymphocytic": 0.5273306369781494, "venclexta": 0.49218109250068665, "leukemia": 0.48143136501312256, "leukaemia": 0.47676289081573486, "lymphocytic": 0.4743087887763977, "lymphoma": 0.4736174941062927, "leukemia hematology": 0.45307886600494385, "cancer therapy": 0.41634583473205566, "chemotherapy": 0.41497981548309326, "chemotherapy free": 0.40929776430130005, "small lymphocytic": 0.4088776707649231, "cell malignancies": 0.4077896475791931, "lymphocyte count": 0.4036398231983185, "hematologic malignancies": 0.40042364597320557, "malignancies": 0.3894660472869873, "tumor lysis": 0.3846626877784729, "lymphocyte": 0.38014453649520874, "follicular lymphoma": 0.3760887384414673, "cell therapy": 0.3737538456916809, "lymph nodes": 0.3730470836162567, "oncology": 0.366646945476532, "tg therapeutics": 0.3656386137008667, "blood cancers": 0.3618593215942383, "therapeutics announces": 0.3533787131309509, "btk inhibitors": 0.3519688844680786, "btk inhibitor": 0.349902480840683, "cancer network": 0.3445237874984741, "blood cancer": 0.33953434228897095, "immunotherapy": 0.3394342064857483, "cancer center": 0.3333044648170471, "wbc": 0.33062249422073364, "hematologist oncologist": 0.3291902542114258, "lymphocytes": 0.3247499465942383, "clinical trials": 0.32309356331825256, "rituximab combo": 0.3174368143081665, "plus obinutuzumab": 0.31644511222839355, "targeted therapies": 0.3161983788013458, "cancer survivors": 0.3155616521835327, "newly diagnosed": 0.31447213888168335, "combination therapies": 0.3103675842285156, "targeted therapy": 0.3096436560153961, "plus rituximab": 0.30926722288131714, "lymph": 0.30925261974334717, "rituxan": 0.30480343103408813}, "12": {"lymphocytic leukaemia": 0.5974857807159424, "lymphocytic leukemia": 0.5874141454696655, "chronic lymphocytic": 0.4931601881980896, "ibrutinib plus": 0.49191832542419434, "ibrutinib": 0.48361217975616455, "leukaemia": 0.48020389676094055, "leukemia": 0.4338787794113159, "leukemia hematology": 0.4269673824310303, "lymphocytic": 0.411444753408432, "plus obinutuzumab": 0.4056472182273865, "venetoclax obinutuzumab": 0.3953070640563965, "lymphoma": 0.3849208950996399, "cancer therapy": 0.3803817331790924, "chemotherapy": 0.3796118199825287, "immunotherapy": 0.37513822317123413, "hematologic malignancies": 0.36931008100509644, "btk inhibitors": 0.369255006313324, "btk inhibitor": 0.36791980266571045, "obinutuzumab": 0.3626862168312073, "obinutuzumab combo": 0.36061233282089233, "cell malignancies": 0.357698917388916, "small lymphocytic": 0.34818750619888306, "chemotherapy free": 0.3403286933898926, "malignancies": 0.3384363055229187, "cell therapy": 0.32342690229415894, "clinical trials": 0.3214985132217407, "blood cancers": 0.3139640688896179, "plus rituximab": 0.3047219514846802, "targeted therapy": 0.3036634624004364, "follicular lymphoma": 0.3006651997566223, "targeted therapies": 0.2997443974018097, "oncology": 0.29767295718193054, "lymphocyte count": 0.2957803010940552, "wbc": 0.29563838243484497, "btk inhibition": 0.29468342661857605, "blood cancer": 0.2937387228012085, "clinical trial": 0.28370195627212524, "my wbc": 0.27938228845596313, "lymphocyte": 0.27787506580352783, "rituximab combo": 0.27747178077697754, "newly diagnosed": 0.2769361138343811, "disease progression": 0.2760818600654602, "treatments": 0.27332621812820435, "inhibitors": 0.2732963562011719, "hematologist oncologist": 0.2720118761062622, "immune response": 0.270760715007782, "treatment options": 0.26797452569007874, "antibodies": 0.267884224653244, "therapeutics announces": 0.2666235864162445, "combination therapies": 0.2652532458305359}, "13": {"plus obinutuzumab": 0.5013941526412964, "umbralisib ublituximab": 0.4980846047401428, "obinutuzumab combo": 0.48307955265045166, "venetoclax obinutuzumab": 0.47625118494033813, "obinutuzumab": 0.4434802532196045, "umbralisib": 0.44140830636024475, "acalabrutinib demonstrates": 0.4392169117927551, "ublituximab plus": 0.43508800864219666, "plus rituximab": 0.4246369004249573, "rituximab combo": 0.42426490783691406, "refractory cll": 0.4134790897369385, "ublituximab": 0.4056655764579773, "ibrutinib plus": 0.3905141353607178, "cll": 0.3767421245574951, "targeted therapies": 0.3761056363582611, "rituximab": 0.37440600991249084, "acalabrutinib": 0.3682544529438019, "acalabrutinib shows": 0.3641132712364197, "combination therapies": 0.3582134246826172, "ibrutinib": 0.35574737191200256, "clinical trials": 0.3485846519470215, "plus venetoclax": 0.3467091917991638, "clinical trial": 0.3462344706058502, "btk inhibitors": 0.3414420485496521, "therapeutics announces": 0.3401411771774292, "venetoclax based": 0.33246979117393494, "treatment options": 0.33033519983291626, "cancer therapy": 0.32761716842651367, "treatment": 0.32752367854118347, "btk inhibitor": 0.3273656368255615, "targeted therapy": 0.32714658975601196, "inhibitors": 0.32523682713508606, "wbc": 0.3232271373271942, "treatments": 0.31455665826797485, "inhibitor": 0.30964750051498413, "cll sll": 0.30717259645462036, "fda approval": 0.30343976616859436, "tg therapeutics": 0.30002808570861816, "venetoclax": 0.29717153310775757, "treatment landscape": 0.2960919141769409, "fda approves": 0.2937687039375305, "pi inhibitors": 0.29095959663391113, "previously treated": 0.2905898690223694, "treatment naive": 0.28832563757896423, "rituxan": 0.2867567539215088, "btk inhibition": 0.2854183316230774, "cirmtuzumab": 0.2851986885070801, "mcl": 0.281456857919693, "monotherapy": 0.2786332964897156, "my wbc": 0.2769496440887451}, "14": {"zanubrutinib": 0.7301791906356812, "acalabrutinib demonstrates": 0.46114581823349, "plus obinutuzumab": 0.42975568771362305, "acalabrutinib": 0.4222087264060974, "ibrutinib": 0.40520915389060974, "ibrutinib plus": 0.40481722354888916, "btk inhibitors": 0.40394312143325806, "obinutuzumab": 0.40200650691986084, "btk inhibitor": 0.3902505934238434, "inhibitors": 0.3846096396446228, "venetoclax obinutuzumab": 0.384299099445343, "obinutuzumab combo": 0.38356101512908936, "chemotherapy": 0.38088393211364746, "cancer therapy": 0.36959677934646606, "acalabrutinib shows": 0.3622075915336609, "inhibitor": 0.3607741594314575, "pi inhibitors": 0.35750317573547363, "plus rituximab": 0.3540101647377014, "chemotherapy free": 0.3476618528366089, "btk inhibition": 0.33822599053382874, "targeted therapies": 0.3378943204879761, "targeted therapy": 0.337024450302124, "rituximab combo": 0.3246304392814636, "combination therapies": 0.31600016355514526, "rituximab": 0.3157005310058594, "cirmtuzumab": 0.3110228180885315, "treatment": 0.30550557374954224, "clinical trials": 0.3040698766708374, "leukaemia": 0.30357038974761963, "lymphocytic leukaemia": 0.301641047000885, "treatment naive": 0.2981645166873932, "clinical trial": 0.29463765025138855, "treatment options": 0.29397276043891907, "treatments": 0.29276594519615173, "lymphocytic leukemia": 0.2880016267299652, "immunotherapy": 0.28726986050605774, "cll": 0.284668505191803, "leukemia": 0.2827431559562683, "refractory cll": 0.28158217668533325, "cell therapy": 0.27999961376190186, "treatment landscape": 0.27691298723220825, "venclexta": 0.27402228116989136, "rituxan": 0.27285143733024597, "oncology": 0.26768094301223755, "therapeutics announces": 0.26706400513648987, "tg therapeutics": 0.2645462155342102, "leukemia hematology": 0.25826138257980347, "malignancies": 0.24741175770759583, "chemo": 0.24662244319915771, "wbc": 0.24392879009246826}, "15": {"imbruvica": 0.5101805925369263, "venetoclax obinutuzumab": 0.4498002231121063, "treatment options": 0.43678876757621765, "plus obinutuzumab": 0.410321980714798, "immunotherapy": 0.40450090169906616, "btk inhibitors": 0.3933083415031433, "clinical trials": 0.3888363838195801, "treatment": 0.3883223831653595, "clinical trial": 0.3880350589752197, "combination therapies": 0.38802552223205566, "btk inhibitor": 0.38416385650634766, "targeted therapies": 0.3812001347541809, "treatments": 0.3803805112838745, "tg therapeutics": 0.3801330327987671, "cancer therapy": 0.3782272934913635, "obinutuzumab combo": 0.376298725605011, "therapeutics announces": 0.37346330285072327, "treatment landscape": 0.3726244568824768, "obinutuzumab": 0.36024534702301025, "targeted therapy": 0.3584177792072296, "cll": 0.3553053140640259, "refractory cll": 0.3529432415962219, "patients with chronic": 0.35072314739227295, "chemotherapy free": 0.34891536831855774, "acalabrutinib demonstrates": 0.3389349579811096, "treatment naive": 0.32997316122055054, "monotherapy": 0.32836249470710754, "plus rituximab": 0.32832130789756775, "cell therapy": 0.3274337947368622, "btk inhibition": 0.32731911540031433, "chemotherapy": 0.326232373714447, "pi inhibitors": 0.3247455656528473, "inhibitors": 0.32314902544021606, "was diagnosed": 0.3231363892555237, "ibrutinib plus": 0.3227413296699524, "previously treated": 0.32204699516296387, "newly diagnosed": 0.32135438919067383, "plus venetoclax": 0.3194197118282318, "cll sll": 0.31739386916160583, "lymphocytic leukaemia": 0.31596481800079346, "lymphoma": 0.3125295639038086, "therapeutics": 0.30912572145462036, "leukaemia": 0.3066101670265198, "fda approves": 0.30579838156700134, "treatment paradigm": 0.30573195219039917, "fda approval": 0.3055185377597809, "patients": 0.3017597794532776, "rituximab combo": 0.3015023171901703, "venetoclax based": 0.3007762134075165, "malignancies": 0.29849773645401}, "16": {"undetectable mrd": 0.5972979068756104, "mrd": 0.5184475779533386, "cll": 0.45327526330947876, "refractory cll": 0.44718191027641296, "cll sll": 0.3756902813911438, "was diagnosed": 0.3466249704360962, "newly diagnosed": 0.32607603073120117, "mcl": 0.321308434009552, "diagnosed": 0.31355178356170654, "patients with chronic": 0.3113156259059906, "disease progression": 0.30434051156044006, "clinical trials": 0.30225980281829834, "clinical trial": 0.29151207208633423, "clinical": 0.28972259163856506, "cancer therapy": 0.28964918851852417, "leukemia": 0.28953781723976135, "tg therapeutics": 0.28705519437789917, "therapeutics announces": 0.28478875756263733, "dr abedin": 0.28117862343788147, "treatments": 0.27762216329574585, "targeted therapies": 0.27724751830101013, "dr": 0.27666908502578735, "dr davids": 0.2765575349330902, "dr brander": 0.2746865749359131, "targeted therapy": 0.2727057933807373, "tumor lysis": 0.2716449499130249, "my wbc": 0.27154070138931274, "diagnosis": 0.2706550061702728, "btk inhibitor": 0.268066942691803, "dr byrd": 0.26751959323883057, "previously treated": 0.267320841550827, "btk inhibitors": 0.26627349853515625, "lymphoma": 0.265781968832016, "wbc": 0.26532402634620667, "treatment": 0.26416075229644775, "treatment options": 0.263990193605423, "treatment landscape": 0.2623732089996338, "leukaemia": 0.2622944712638855, "immunotherapy": 0.2595311105251312, "prognostic": 0.2588309049606323, "hematology advisor": 0.25846341252326965, "combination therapies": 0.2564767897129059, "patients": 0.2544907331466675, "hematologist oncologist": 0.2540590763092041, "btk inhibition": 0.2532084882259369, "prognostic factors": 0.24488066136837006, "lymphocytic leukemia": 0.24481359124183655, "dr danilov": 0.24038363993167877, "refractory chronic": 0.237897127866745, "combination therapy": 0.2371223270893097}, "17": {"acalabrutinib demonstrates": 0.6467368006706238, "acalabrutinib": 0.6306655406951904, "ibrutinib plus": 0.5577926635742188, "acalabrutinib shows": 0.5547424554824829, "ibrutinib": 0.5542356371879578, "plus obinutuzumab": 0.47106775641441345, "zanubrutinib": 0.45744937658309937, "obinutuzumab": 0.4445594549179077, "obinutuzumab combo": 0.4121848940849304, "btk inhibitors": 0.408285915851593, "btk inhibitor": 0.3923739790916443, "venetoclax obinutuzumab": 0.36590874195098877, "inhibitors": 0.35527586936950684, "plus rituximab": 0.3436175286769867, "inhibitor": 0.32765740156173706, "btk inhibition": 0.31987568736076355, "refractory cll": 0.3034436106681824, "treatment options": 0.298551082611084, "rituximab": 0.28942185640335083, "treatment": 0.288457453250885, "cirmtuzumab": 0.2874404788017273, "imbruvica": 0.2873901128768921, "rituximab combo": 0.28101953864097595, "combination therapies": 0.2805646061897278, "fda approval": 0.27255547046661377, "pi inhibitors": 0.2667638659477234, "treatments": 0.26563510298728943, "targeted therapies": 0.2655926048755646, "fda approves": 0.26441672444343567, "immunotherapy": 0.26307085156440735, "fda": 0.26209020614624023, "targeted therapy": 0.258226215839386, "therapeutics announces": 0.2551659345626831, "cll": 0.252420037984848, "treatment landscape": 0.25021544098854065, "dr abedin": 0.24871334433555603, "clinical trial": 0.2481878101825714, "clinical trials": 0.24642735719680786, "abbvie": 0.2457599937915802, "treatment naive": 0.23814868927001953, "safety and efficacy": 0.23756614327430725, "tg therapeutics": 0.236122265458107, "monotherapy": 0.23413538932800293, "cancer therapy": 0.2330048531293869, "side effects": 0.23099857568740845, "efficacy and safety": 0.23016880452632904, "therapeutics": 0.2297918200492859, "previously treated": 0.22632934153079987, "chemotherapy": 0.2215431183576584, "refractory chronic": 0.22005878388881683}, "18": {"venetoclax obinutuzumab": 0.5691750049591064, "plus venetoclax": 0.522014319896698, "venetoclax": 0.5073965787887573, "venetoclax based": 0.5032964944839478, "undetectable mrd": 0.4379510283470154, "plus obinutuzumab": 0.3864268660545349, "venclexta": 0.3646678030490875, "refractory cll": 0.3619467616081238, "obinutuzumab combo": 0.3529147505760193, "cll": 0.3514382243156433, "plus rituximab": 0.34749430418014526, "rituximab combo": 0.32825028896331787, "btk inhibitors": 0.32049819827079773, "btk inhibitor": 0.3154216706752777, "obinutuzumab": 0.3110703229904175, "mrd": 0.299999475479126, "cll sll": 0.29900652170181274, "ibrutinib plus": 0.2916807234287262, "btk inhibition": 0.28451424837112427, "lymphoma": 0.27521276473999023, "combination therapies": 0.2723705470561981, "rituximab": 0.26968467235565186, "was diagnosed": 0.2639838457107544, "wbc": 0.26368069648742676, "targeted therapies": 0.2635718882083893, "immunotherapy": 0.26351678371429443, "tg therapeutics": 0.2623540163040161, "rituxan": 0.2620680034160614, "lymphocytic leukemia": 0.2603415846824646, "inhibitors": 0.25819921493530273, "lymphocytic leukaemia": 0.2537824213504791, "mcl": 0.2531123757362366, "my wbc": 0.24828693270683289, "treatment options": 0.24814030528068542, "clinical trials": 0.24273541569709778, "therapeutics announces": 0.24214521050453186, "previously treated": 0.2420116811990738, "chronic lymphocytic": 0.24136492609977722, "newly diagnosed": 0.24020539224147797, "pi inhibitors": 0.23990723490715027, "ibrutinib": 0.23523464798927307, "targeted therapy": 0.23383358120918274, "treatments": 0.2328927367925644, "disease progression": 0.23123429715633392, "cancer therapy": 0.23116640746593475, "lymph nodes": 0.22978420555591583, "clinical trial": 0.2297763079404831, "inhibitor": 0.22600431740283966, "leukaemia": 0.22350047528743744, "patients with chronic": 0.22322100400924683}, "19": {"acalabrutinib": 0.600602388381958, "acalabrutinib demonstrates": 0.5907238125801086, "acalabrutinib shows": 0.5631131529808044, "lymphocytic leukemia": 0.5533318519592285, "lymphocytic leukaemia": 0.5271016955375671, "leukemia hematology": 0.4349108040332794, "chronic lymphocytic": 0.43303367495536804, "leukemia": 0.43065983057022095, "zanubrutinib": 0.42407992482185364, "leukaemia": 0.41156792640686035, "cancer therapy": 0.3952813446521759, "plus obinutuzumab": 0.38909590244293213, "blood cancers": 0.3817557692527771, "hematologic malignancies": 0.3813517093658447, "lymphocytic": 0.3762291669845581, "obinutuzumab": 0.37101995944976807, "cell malignancies": 0.37020593881607056, "obinutuzumab combo": 0.3672013282775879, "blood cancer": 0.35991281270980835, "malignancies": 0.356700599193573, "btk inhibitor": 0.35636061429977417, "btk inhibitors": 0.3558530807495117, "chemotherapy": 0.3549783527851105, "immunotherapy": 0.3350253701210022, "chemotherapy free": 0.32863396406173706, "oncology": 0.32746216654777527, "cell therapy": 0.32660752534866333, "small lymphocytic": 0.32029110193252563, "lymphoma": 0.32016652822494507, "venetoclax obinutuzumab": 0.3187639117240906, "hematologist oncologist": 0.3152397871017456, "ibrutinib plus": 0.3039480745792389, "ibrutinib": 0.3009762465953827, "cancers": 0.29694005846977234, "cancer": 0.2950500547885895, "targeted therapy": 0.2912876605987549, "targeted therapies": 0.28502729535102844, "hematology advisor": 0.2815410792827606, "btk inhibition": 0.27786701917648315, "cancer survivors": 0.2751496434211731, "cirmtuzumab": 0.2737416625022888, "tumor lysis": 0.26804405450820923, "inhibitors": 0.2640489339828491, "therapeutics announces": 0.26267093420028687, "imbruvica": 0.26161473989486694, "follicular lymphoma": 0.2596011757850647, "cancer center": 0.258558988571167, "combination therapies": 0.25581032037734985, "treatment": 0.25534817576408386, "newly diagnosed": 0.25495266914367676}, "20": {"venetoclax obinutuzumab": 0.6245009899139404, "lymphocytic leukemia": 0.6220284700393677, "lymphocytic leukaemia": 0.6135941743850708, "venetoclax": 0.5236256122589111, "chronic lymphocytic": 0.5212589502334595, "venetoclax based": 0.5137815475463867, "plus venetoclax": 0.5117152333259583, "lymphocytic": 0.459553599357605, "leukaemia": 0.45381906628608704, "lymphoma": 0.4270532727241516, "leukemia": 0.41624340415000916, "plus obinutuzumab": 0.4120887517929077, "leukemia hematology": 0.407450795173645, "small lymphocytic": 0.40273183584213257, "ibrutinib plus": 0.3967537581920624, "obinutuzumab combo": 0.38136619329452515, "cell malignancies": 0.3739355206489563, "ibrutinib": 0.36532092094421387, "hematologic malignancies": 0.3646177649497986, "immunotherapy": 0.3633963465690613, "btk inhibitor": 0.36116844415664673, "obinutuzumab": 0.3603208661079407, "follicular lymphoma": 0.3593071699142456, "btk inhibitors": 0.35918569564819336, "venclexta": 0.3562006950378418, "chemotherapy": 0.3457013964653015, "lymphocyte": 0.3428519368171692, "lymphocyte count": 0.3365243077278137, "cancer therapy": 0.335385799407959, "wbc": 0.33431634306907654, "malignancies": 0.3275185227394104, "cell therapy": 0.3233276605606079, "plus rituximab": 0.3132398724555969, "rituximab combo": 0.3029659688472748, "chemotherapy free": 0.2981854975223541, "blood cancers": 0.2960776090621948, "lymph nodes": 0.2949052155017853, "my wbc": 0.29120567440986633, "lymphocytes": 0.2887157201766968, "btk inhibition": 0.2856336832046509, "combination therapies": 0.27884092926979065, "antibodies": 0.275870680809021, "tumor lysis": 0.2748449146747589, "oncology": 0.27131837606430054, "inhibitors": 0.27091673016548157, "targeted therapy": 0.26978856325149536, "blood cancer": 0.26493892073631287, "targeted therapies": 0.2648811340332031, "tg therapeutics": 0.264862596988678, "rituximab": 0.2572043538093567}}